Drug resistance mutation analysis of HIV-1 among blood donors in Dalian: 2011—2020
10.13303/j.cjbt.issn.1004-549x.2024.08.010
- VernacularTitle:2011—2020年大连市无偿献血人群HIV-1耐药性突变分析
- Author:
Xiaohan GUO
1
;
Xuelian DENG
1
;
Xiaochun LIU
1
;
Yingying WANG
1
;
Liang ZANG
1
;
Jun ZHOU
2
Author Information
1. Dalian Blood Center, Dalian 116001, China
2. Sansure Biotech Inc
- Publication Type:Journal Article
- Keywords:
HIV-1;
drug resistance mutation;
blood donor
- From:
Chinese Journal of Blood Transfusion
2024;37(8):902-907
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To study the distribution and trend of HIV-1 drug resistance mutation in Dalian blood donors between 2011 and 2020. 【Methods】 The protease-reverse transcriptase (PR-RT) region was sequenced in Dalian blood donors tested HIV-1 positive between 2011 and 2020. Drug resistance mutation (DRM) rate and level of resistance to selected drugs were analyzed by the Stanford HIV Drug Resistance Database. 【Results】 DRM were detected in 17.2% (30/174) of samples, while transmitted drug resistance (TDR) was 5.7% (10/174). Between 2011 and 2020, DRM and TDR rates increased significantly in 2019 and reached their highest levels in 2020 (44.4% and 22.2%, respectively). DRM carriage was associated with people with college degree or above and with local residents (P<0.05). NNRTI DRMs were the most frequently detected (12.6%, 22/174), followed by PIs (5.7%, 10/174), with V179D/E/T and M46I being the main DRMs detected. Only one HIV-1 strain (0.57%, 1/174) carried a NRTI DRM (L74I). The overall rate of predicted high level resistance to antiretroviral drugs was 6.9% (12/174), with the highest proportion of NNRTI resistance (83.3%, 10/12). Two samples were classified as highly resistant to EFV and NVP, accounting for 1.1% (2/174). CRF55_01B strains showed a significantly higher DRM rate than strains of other HIV-1 genotypes (P<0.05). 【Conclusion】 Between 2011 and 2020, the rate of HIV-1 DRMs in blood donors in Dalian showed a significant upward trend, particularly in 2019—2020, with NNRTI resistance being the most common. The combination of DRMs detection before and after implementation of ART under the latest national ART treatment plan would improve the effectiveness of HIV-1 prevention and control locally.
